nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepenzolate—Erectile dysfunction—Sitagliptin—type 2 diabetes mellitus	0.00522	0.00751	CcSEcCtD
Mepenzolate—Anaphylactic shock—Linagliptin—type 2 diabetes mellitus	0.00517	0.00743	CcSEcCtD
Mepenzolate—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.00507	0.00729	CcSEcCtD
Mepenzolate—Abdominal distension—Glyburide—type 2 diabetes mellitus	0.00472	0.00679	CcSEcCtD
Mepenzolate—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.00458	0.00658	CcSEcCtD
Mepenzolate—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.00456	0.00656	CcSEcCtD
Mepenzolate—Palpitations—Repaglinide—type 2 diabetes mellitus	0.00454	0.00652	CcSEcCtD
Mepenzolate—Constipation—Linagliptin—type 2 diabetes mellitus	0.00442	0.00636	CcSEcCtD
Mepenzolate—Feeling abnormal—Tolazamide—type 2 diabetes mellitus	0.00431	0.00619	CcSEcCtD
Mepenzolate—Constipation—Acarbose—type 2 diabetes mellitus	0.00429	0.00617	CcSEcCtD
Mepenzolate—Abdominal distension—Gliclazide—type 2 diabetes mellitus	0.00424	0.0061	CcSEcCtD
Mepenzolate—Anaphylactic shock—Repaglinide—type 2 diabetes mellitus	0.00419	0.00602	CcSEcCtD
Mepenzolate—Tension—Glipizide—type 2 diabetes mellitus	0.00417	0.00599	CcSEcCtD
Mepenzolate—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.00415	0.00597	CcSEcCtD
Mepenzolate—Urticaria—Tolazamide—type 2 diabetes mellitus	0.00415	0.00597	CcSEcCtD
Mepenzolate—Nervousness—Glipizide—type 2 diabetes mellitus	0.00413	0.00593	CcSEcCtD
Mepenzolate—Urticaria—Linagliptin—type 2 diabetes mellitus	0.00411	0.00591	CcSEcCtD
Mepenzolate—Vision blurred—Glipizide—type 2 diabetes mellitus	0.004	0.00575	CcSEcCtD
Mepenzolate—Urticaria—Acarbose—type 2 diabetes mellitus	0.00399	0.00573	CcSEcCtD
Mepenzolate—Anaphylactic shock—Rosiglitazone—type 2 diabetes mellitus	0.00396	0.00569	CcSEcCtD
Mepenzolate—Tension—Glimepiride—type 2 diabetes mellitus	0.00389	0.00559	CcSEcCtD
Mepenzolate—Erectile dysfunction—Gliclazide—type 2 diabetes mellitus	0.00388	0.00558	CcSEcCtD
Mepenzolate—Tension—Sitagliptin—type 2 diabetes mellitus	0.00388	0.00557	CcSEcCtD
Mepenzolate—Abdominal distension—Orlistat—type 2 diabetes mellitus	0.00385	0.00554	CcSEcCtD
Mepenzolate—Nervousness—Glimepiride—type 2 diabetes mellitus	0.00385	0.00553	CcSEcCtD
Mepenzolate—Urticaria—Nateglinide—type 2 diabetes mellitus	0.00385	0.00553	CcSEcCtD
Mepenzolate—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.00384	0.00552	CcSEcCtD
Mepenzolate—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.00381	0.00548	CcSEcCtD
Mepenzolate—Nausea—Miglitol—type 2 diabetes mellitus	0.00379	0.00545	CcSEcCtD
Mepenzolate—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.00376	0.0054	CcSEcCtD
Mepenzolate—Asthenia—Tolazamide—type 2 diabetes mellitus	0.00375	0.00539	CcSEcCtD
Mepenzolate—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.00374	0.00537	CcSEcCtD
Mepenzolate—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.00372	0.00535	CcSEcCtD
Mepenzolate—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.0037	0.00532	CcSEcCtD
Mepenzolate—Headache—Tolbutamide—type 2 diabetes mellitus	0.0036	0.00517	CcSEcCtD
Mepenzolate—Constipation—Repaglinide—type 2 diabetes mellitus	0.00358	0.00515	CcSEcCtD
Mepenzolate—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.00357	0.00513	CcSEcCtD
Mepenzolate—Erectile dysfunction—Valsartan—type 2 diabetes mellitus	0.00357	0.00512	CcSEcCtD
Mepenzolate—Abdominal distension—Metformin—type 2 diabetes mellitus	0.00355	0.0051	CcSEcCtD
Mepenzolate—Tension—Bromocriptine—type 2 diabetes mellitus	0.00351	0.00504	CcSEcCtD
Mepenzolate—Palpitations—Glimepiride—type 2 diabetes mellitus	0.0035	0.00504	CcSEcCtD
Mepenzolate—Confusional state—Glipizide—type 2 diabetes mellitus	0.0035	0.00502	CcSEcCtD
Mepenzolate—Asthenia—Nateglinide—type 2 diabetes mellitus	0.00347	0.00499	CcSEcCtD
Mepenzolate—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.00347	0.00499	CcSEcCtD
Mepenzolate—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00346	0.00497	CcSEcCtD
Mepenzolate—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00346	0.00497	CcSEcCtD
Mepenzolate—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00341	0.0049	CcSEcCtD
Mepenzolate—Constipation—Rosiglitazone—type 2 diabetes mellitus	0.00339	0.00487	CcSEcCtD
Mepenzolate—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.00337	0.00484	CcSEcCtD
Mepenzolate—Abdominal distension—Irbesartan—type 2 diabetes mellitus	0.00335	0.00481	CcSEcCtD
Mepenzolate—Urticaria—Repaglinide—type 2 diabetes mellitus	0.00333	0.00479	CcSEcCtD
Mepenzolate—Vomiting—Chlorpropamide—type 2 diabetes mellitus	0.00332	0.00478	CcSEcCtD
Mepenzolate—Anaphylactic shock—Pioglitazone—type 2 diabetes mellitus	0.00332	0.00477	CcSEcCtD
Mepenzolate—Dry mouth—Glimepiride—type 2 diabetes mellitus	0.0033	0.00474	CcSEcCtD
Mepenzolate—Dry mouth—Sitagliptin—type 2 diabetes mellitus	0.00329	0.00473	CcSEcCtD
Mepenzolate—Headache—Tolazamide—type 2 diabetes mellitus	0.00327	0.00471	CcSEcCtD
Mepenzolate—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00327	0.00471	CcSEcCtD
Mepenzolate—Confusional state—Glimepiride—type 2 diabetes mellitus	0.00326	0.00469	CcSEcCtD
Mepenzolate—Headache—Linagliptin—type 2 diabetes mellitus	0.00324	0.00466	CcSEcCtD
Mepenzolate—Anaphylactic shock—Glimepiride—type 2 diabetes mellitus	0.00324	0.00465	CcSEcCtD
Mepenzolate—Anaphylactic shock—Sitagliptin—type 2 diabetes mellitus	0.00323	0.00464	CcSEcCtD
Mepenzolate—Dizziness—Nateglinide—type 2 diabetes mellitus	0.0032	0.0046	CcSEcCtD
Mepenzolate—Vomiting—Acarbose—type 2 diabetes mellitus	0.00319	0.00459	CcSEcCtD
Mepenzolate—Tachycardia—Glimepiride—type 2 diabetes mellitus	0.00316	0.00454	CcSEcCtD
Mepenzolate—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00315	0.00452	CcSEcCtD
Mepenzolate—Drowsiness—Metformin—type 2 diabetes mellitus	0.00314	0.00452	CcSEcCtD
Mepenzolate—Insomnia—Glipizide—type 2 diabetes mellitus	0.00314	0.00451	CcSEcCtD
Mepenzolate—Nausea—Tolazamide—type 2 diabetes mellitus	0.0031	0.00446	CcSEcCtD
Mepenzolate—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.0031	0.00446	CcSEcCtD
Mepenzolate—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00309	0.00444	CcSEcCtD
Mepenzolate—Somnolence—Glipizide—type 2 diabetes mellitus	0.00308	0.00443	CcSEcCtD
Mepenzolate—Vision blurred—Glyburide—type 2 diabetes mellitus	0.00308	0.00443	CcSEcCtD
Mepenzolate—Vomiting—Nateglinide—type 2 diabetes mellitus	0.00308	0.00442	CcSEcCtD
Mepenzolate—Insomnia—Pioglitazone—type 2 diabetes mellitus	0.003	0.00432	CcSEcCtD
Mepenzolate—Nausea—Acarbose—type 2 diabetes mellitus	0.00298	0.00429	CcSEcCtD
Mepenzolate—Dry mouth—Bromocriptine—type 2 diabetes mellitus	0.00298	0.00428	CcSEcCtD
Mepenzolate—Constipation—Glipizide—type 2 diabetes mellitus	0.00297	0.00426	CcSEcCtD
Mepenzolate—Confusional state—Bromocriptine—type 2 diabetes mellitus	0.00294	0.00423	CcSEcCtD
Mepenzolate—Insomnia—Glimepiride—type 2 diabetes mellitus	0.00293	0.00421	CcSEcCtD
Mepenzolate—Insomnia—Sitagliptin—type 2 diabetes mellitus	0.00292	0.00419	CcSEcCtD
Mepenzolate—Erectile dysfunction—Losartan—type 2 diabetes mellitus	0.00288	0.00414	CcSEcCtD
Mepenzolate—Tension—Gliclazide—type 2 diabetes mellitus	0.00288	0.00414	CcSEcCtD
Mepenzolate—Somnolence—Glimepiride—type 2 diabetes mellitus	0.00288	0.00413	CcSEcCtD
Mepenzolate—Nausea—Nateglinide—type 2 diabetes mellitus	0.00288	0.00413	CcSEcCtD
Mepenzolate—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.00287	0.00412	CcSEcCtD
Mepenzolate—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.00286	0.00411	CcSEcCtD
Mepenzolate—Nervousness—Gliclazide—type 2 diabetes mellitus	0.00285	0.0041	CcSEcCtD
Mepenzolate—Tachycardia—Bromocriptine—type 2 diabetes mellitus	0.00285	0.00409	CcSEcCtD
Mepenzolate—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.00284	0.00408	CcSEcCtD
Mepenzolate—Constipation—Sitagliptin—type 2 diabetes mellitus	0.00276	0.00396	CcSEcCtD
Mepenzolate—Urticaria—Glipizide—type 2 diabetes mellitus	0.00275	0.00396	CcSEcCtD
Mepenzolate—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.00274	0.00393	CcSEcCtD
Mepenzolate—Confusional state—Glyburide—type 2 diabetes mellitus	0.00269	0.00387	CcSEcCtD
Mepenzolate—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.00267	0.00383	CcSEcCtD
Mepenzolate—Vomiting—Repaglinide—type 2 diabetes mellitus	0.00266	0.00383	CcSEcCtD
Mepenzolate—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.00266	0.00382	CcSEcCtD
Mepenzolate—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.00264	0.00379	CcSEcCtD
Mepenzolate—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00264	0.00379	CcSEcCtD
Mepenzolate—Headache—Repaglinide—type 2 diabetes mellitus	0.00263	0.00377	CcSEcCtD
Mepenzolate—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00262	0.00376	CcSEcCtD
Mepenzolate—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.00259	0.00373	CcSEcCtD
Mepenzolate—Palpitations—Gliclazide—type 2 diabetes mellitus	0.00259	0.00373	CcSEcCtD
Mepenzolate—Urticaria—Glimepiride—type 2 diabetes mellitus	0.00257	0.00369	CcSEcCtD
Mepenzolate—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.00256	0.00368	CcSEcCtD
Mepenzolate—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00255	0.00367	CcSEcCtD
Mepenzolate—Vision blurred—Valsartan—type 2 diabetes mellitus	0.00254	0.00365	CcSEcCtD
Mepenzolate—Vision blurred—Orlistat—type 2 diabetes mellitus	0.00251	0.00361	CcSEcCtD
Mepenzolate—Constipation—Bromocriptine—type 2 diabetes mellitus	0.0025	0.00359	CcSEcCtD
Mepenzolate—Nausea—Repaglinide—type 2 diabetes mellitus	0.00249	0.00358	CcSEcCtD
Mepenzolate—Asthenia—Glipizide—type 2 diabetes mellitus	0.00249	0.00358	CcSEcCtD
Mepenzolate—Headache—Rosiglitazone—type 2 diabetes mellitus	0.00248	0.00357	CcSEcCtD
Mepenzolate—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.00247	0.00355	CcSEcCtD
Mepenzolate—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00245	0.00352	CcSEcCtD
Mepenzolate—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.00244	0.00351	CcSEcCtD
Mepenzolate—Loperamide—CALM1—type 2 diabetes mellitus	0.00243	0.325	CrCbGaD
Mepenzolate—Confusional state—Gliclazide—type 2 diabetes mellitus	0.00242	0.00347	CcSEcCtD
Mepenzolate—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.00241	0.00346	CcSEcCtD
Mepenzolate—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00238	0.00343	CcSEcCtD
Mepenzolate—Palpitations—Valsartan—type 2 diabetes mellitus	0.00238	0.00343	CcSEcCtD
Mepenzolate—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00238	0.00343	CcSEcCtD
Mepenzolate—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00238	0.00342	CcSEcCtD
Mepenzolate—Palpitations—Orlistat—type 2 diabetes mellitus	0.00236	0.00339	CcSEcCtD
Mepenzolate—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00235	0.00338	CcSEcCtD
Mepenzolate—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.00234	0.00336	CcSEcCtD
Mepenzolate—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00232	0.00334	CcSEcCtD
Mepenzolate—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00232	0.00333	CcSEcCtD
Mepenzolate—Vision blurred—Metformin—type 2 diabetes mellitus	0.00231	0.00333	CcSEcCtD
Mepenzolate—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00231	0.00333	CcSEcCtD
Mepenzolate—Dizziness—Glipizide—type 2 diabetes mellitus	0.00229	0.0033	CcSEcCtD
Mepenzolate—Tension—Irbesartan—type 2 diabetes mellitus	0.00227	0.00327	CcSEcCtD
Mepenzolate—Nervousness—Irbesartan—type 2 diabetes mellitus	0.00225	0.00324	CcSEcCtD
Mepenzolate—Dry mouth—Valsartan—type 2 diabetes mellitus	0.00225	0.00323	CcSEcCtD
Mepenzolate—Dry mouth—Orlistat—type 2 diabetes mellitus	0.00222	0.00319	CcSEcCtD
Mepenzolate—Vomiting—Glipizide—type 2 diabetes mellitus	0.0022	0.00317	CcSEcCtD
Mepenzolate—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.0022	0.00316	CcSEcCtD
Mepenzolate—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.0022	0.00316	CcSEcCtD
Mepenzolate—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.0022	0.00316	CcSEcCtD
Mepenzolate—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.00218	0.00314	CcSEcCtD
Mepenzolate—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.00218	0.00313	CcSEcCtD
Mepenzolate—Headache—Glipizide—type 2 diabetes mellitus	0.00217	0.00312	CcSEcCtD
Mepenzolate—Palpitations—Metformin—type 2 diabetes mellitus	0.00217	0.00312	CcSEcCtD
Mepenzolate—Insomnia—Gliclazide—type 2 diabetes mellitus	0.00217	0.00311	CcSEcCtD
Mepenzolate—Tension—Losartan—type 2 diabetes mellitus	0.00214	0.00308	CcSEcCtD
Mepenzolate—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00214	0.00308	CcSEcCtD
Mepenzolate—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00213	0.00307	CcSEcCtD
Mepenzolate—Somnolence—Gliclazide—type 2 diabetes mellitus	0.00213	0.00306	CcSEcCtD
Mepenzolate—Urticaria—Glyburide—type 2 diabetes mellitus	0.00212	0.00305	CcSEcCtD
Mepenzolate—Nervousness—Losartan—type 2 diabetes mellitus	0.00212	0.00305	CcSEcCtD
Mepenzolate—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00209	0.00301	CcSEcCtD
Mepenzolate—Headache—Pioglitazone—type 2 diabetes mellitus	0.00208	0.00299	CcSEcCtD
Mepenzolate—Nausea—Glipizide—type 2 diabetes mellitus	0.00206	0.00296	CcSEcCtD
Mepenzolate—Vomiting—Glimepiride—type 2 diabetes mellitus	0.00206	0.00296	CcSEcCtD
Mepenzolate—Vision blurred—Losartan—type 2 diabetes mellitus	0.00206	0.00296	CcSEcCtD
Mepenzolate—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.00205	0.00295	CcSEcCtD
Mepenzolate—Constipation—Gliclazide—type 2 diabetes mellitus	0.00205	0.00295	CcSEcCtD
Mepenzolate—Headache—Glimepiride—type 2 diabetes mellitus	0.00203	0.00291	CcSEcCtD
Mepenzolate—Headache—Sitagliptin—type 2 diabetes mellitus	0.00202	0.0029	CcSEcCtD
Mepenzolate—Insomnia—Valsartan—type 2 diabetes mellitus	0.00199	0.00286	CcSEcCtD
Mepenzolate—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.00197	0.00284	CcSEcCtD
Mepenzolate—Insomnia—Orlistat—type 2 diabetes mellitus	0.00197	0.00283	CcSEcCtD
Mepenzolate—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00197	0.00283	CcSEcCtD
Mepenzolate—Somnolence—Valsartan—type 2 diabetes mellitus	0.00196	0.00281	CcSEcCtD
Mepenzolate—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00193	0.00277	CcSEcCtD
Mepenzolate—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.00193	0.00277	CcSEcCtD
Mepenzolate—Palpitations—Losartan—type 2 diabetes mellitus	0.00193	0.00277	CcSEcCtD
Mepenzolate—Nausea—Glimepiride—type 2 diabetes mellitus	0.00192	0.00276	CcSEcCtD
Mepenzolate—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00192	0.00275	CcSEcCtD
Mepenzolate—Asthenia—Glyburide—type 2 diabetes mellitus	0.00191	0.00275	CcSEcCtD
Mepenzolate—Urticaria—Gliclazide—type 2 diabetes mellitus	0.0019	0.00274	CcSEcCtD
Mepenzolate—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.00189	0.00272	CcSEcCtD
Mepenzolate—Constipation—Valsartan—type 2 diabetes mellitus	0.00188	0.00271	CcSEcCtD
Mepenzolate—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.00186	0.00267	CcSEcCtD
Mepenzolate—Tachycardia—Irbesartan—type 2 diabetes mellitus	0.00185	0.00265	CcSEcCtD
Mepenzolate—Tension—Ramipril—type 2 diabetes mellitus	0.00184	0.00264	CcSEcCtD
Mepenzolate—Headache—Bromocriptine—type 2 diabetes mellitus	0.00183	0.00263	CcSEcCtD
Mepenzolate—Nervousness—Ramipril—type 2 diabetes mellitus	0.00182	0.00261	CcSEcCtD
Mepenzolate—Dry mouth—Losartan—type 2 diabetes mellitus	0.00182	0.00261	CcSEcCtD
Mepenzolate—Confusional state—Losartan—type 2 diabetes mellitus	0.0018	0.00258	CcSEcCtD
Mepenzolate—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00179	0.00258	CcSEcCtD
Mepenzolate—Somnolence—Metformin—type 2 diabetes mellitus	0.00178	0.00256	CcSEcCtD
Mepenzolate—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.00178	0.00256	CcSEcCtD
Mepenzolate—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00177	0.00254	CcSEcCtD
Mepenzolate—Urticaria—Valsartan—type 2 diabetes mellitus	0.00175	0.00251	CcSEcCtD
Mepenzolate—Tachycardia—Losartan—type 2 diabetes mellitus	0.00174	0.0025	CcSEcCtD
Mepenzolate—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00173	0.00249	CcSEcCtD
Mepenzolate—Urticaria—Orlistat—type 2 diabetes mellitus	0.00173	0.00248	CcSEcCtD
Mepenzolate—Asthenia—Gliclazide—type 2 diabetes mellitus	0.00172	0.00247	CcSEcCtD
Mepenzolate—Constipation—Metformin—type 2 diabetes mellitus	0.00171	0.00246	CcSEcCtD
Mepenzolate—Vomiting—Glyburide—type 2 diabetes mellitus	0.0017	0.00244	CcSEcCtD
Mepenzolate—Somnolence—Irbesartan—type 2 diabetes mellitus	0.00168	0.00242	CcSEcCtD
Mepenzolate—Headache—Glyburide—type 2 diabetes mellitus	0.00167	0.0024	CcSEcCtD
Mepenzolate—Palpitations—Ramipril—type 2 diabetes mellitus	0.00165	0.00238	CcSEcCtD
Mepenzolate—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.00165	0.00237	CcSEcCtD
Mepenzolate—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00162	0.00233	CcSEcCtD
Mepenzolate—Constipation—Irbesartan—type 2 diabetes mellitus	0.00162	0.00233	CcSEcCtD
Mepenzolate—Insomnia—Losartan—type 2 diabetes mellitus	0.00161	0.00231	CcSEcCtD
Mepenzolate—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.0016	0.0023	CcSEcCtD
Mepenzolate—Urticaria—Metformin—type 2 diabetes mellitus	0.00159	0.00229	CcSEcCtD
Mepenzolate—Nausea—Glyburide—type 2 diabetes mellitus	0.00159	0.00228	CcSEcCtD
Mepenzolate—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00158	0.00228	CcSEcCtD
Mepenzolate—Somnolence—Losartan—type 2 diabetes mellitus	0.00158	0.00227	CcSEcCtD
Mepenzolate—Asthenia—Valsartan—type 2 diabetes mellitus	0.00158	0.00227	CcSEcCtD
Mepenzolate—Asthenia—Orlistat—type 2 diabetes mellitus	0.00156	0.00224	CcSEcCtD
Mepenzolate—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.00156	0.00224	CcSEcCtD
Mepenzolate—Dry mouth—Ramipril—type 2 diabetes mellitus	0.00156	0.00224	CcSEcCtD
Mepenzolate—Confusional state—Ramipril—type 2 diabetes mellitus	0.00154	0.00221	CcSEcCtD
Mepenzolate—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	0.00153	0.00219	CcSEcCtD
Mepenzolate—Vomiting—Gliclazide—type 2 diabetes mellitus	0.00152	0.00219	CcSEcCtD
Mepenzolate—Constipation—Losartan—type 2 diabetes mellitus	0.00152	0.00219	CcSEcCtD
Mepenzolate—Urticaria—Irbesartan—type 2 diabetes mellitus	0.0015	0.00216	CcSEcCtD
Mepenzolate—Headache—Gliclazide—type 2 diabetes mellitus	0.0015	0.00216	CcSEcCtD
Mepenzolate—Tachycardia—Ramipril—type 2 diabetes mellitus	0.00149	0.00214	CcSEcCtD
Mepenzolate—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.00147	0.00211	CcSEcCtD
Mepenzolate—Dizziness—Valsartan—type 2 diabetes mellitus	0.00146	0.00209	CcSEcCtD
Mepenzolate—Dizziness—Orlistat—type 2 diabetes mellitus	0.00144	0.00207	CcSEcCtD
Mepenzolate—Asthenia—Metformin—type 2 diabetes mellitus	0.00144	0.00207	CcSEcCtD
Mepenzolate—Nausea—Gliclazide—type 2 diabetes mellitus	0.00142	0.00205	CcSEcCtD
Mepenzolate—Urticaria—Losartan—type 2 diabetes mellitus	0.00141	0.00203	CcSEcCtD
Mepenzolate—Vomiting—Valsartan—type 2 diabetes mellitus	0.0014	0.00201	CcSEcCtD
Mepenzolate—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.00139	0.002	CcSEcCtD
Mepenzolate—Vomiting—Orlistat—type 2 diabetes mellitus	0.00138	0.00199	CcSEcCtD
Mepenzolate—Insomnia—Ramipril—type 2 diabetes mellitus	0.00138	0.00198	CcSEcCtD
Mepenzolate—Headache—Valsartan—type 2 diabetes mellitus	0.00138	0.00198	CcSEcCtD
Mepenzolate—Headache—Orlistat—type 2 diabetes mellitus	0.00136	0.00196	CcSEcCtD
Mepenzolate—Asthenia—Irbesartan—type 2 diabetes mellitus	0.00136	0.00195	CcSEcCtD
Mepenzolate—Somnolence—Ramipril—type 2 diabetes mellitus	0.00136	0.00195	CcSEcCtD
Mepenzolate—Dizziness—Metformin—type 2 diabetes mellitus	0.00133	0.00191	CcSEcCtD
Mepenzolate—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00131	0.00189	CcSEcCtD
Mepenzolate—Nausea—Valsartan—type 2 diabetes mellitus	0.00131	0.00188	CcSEcCtD
Mepenzolate—Constipation—Ramipril—type 2 diabetes mellitus	0.00131	0.00188	CcSEcCtD
Mepenzolate—Nausea—Orlistat—type 2 diabetes mellitus	0.00129	0.00186	CcSEcCtD
Mepenzolate—Asthenia—Losartan—type 2 diabetes mellitus	0.00128	0.00184	CcSEcCtD
Mepenzolate—Vomiting—Metformin—type 2 diabetes mellitus	0.00127	0.00183	CcSEcCtD
Mepenzolate—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.00126	0.00181	CcSEcCtD
Mepenzolate—Headache—Metformin—type 2 diabetes mellitus	0.00126	0.00181	CcSEcCtD
Mepenzolate—Dizziness—Irbesartan—type 2 diabetes mellitus	0.00125	0.0018	CcSEcCtD
Mepenzolate—Urticaria—Ramipril—type 2 diabetes mellitus	0.00121	0.00174	CcSEcCtD
Mepenzolate—Vomiting—Irbesartan—type 2 diabetes mellitus	0.0012	0.00173	CcSEcCtD
Mepenzolate—Nausea—Metformin—type 2 diabetes mellitus	0.00119	0.00171	CcSEcCtD
Mepenzolate—Headache—Irbesartan—type 2 diabetes mellitus	0.00119	0.0017	CcSEcCtD
Mepenzolate—Dizziness—Losartan—type 2 diabetes mellitus	0.00118	0.00169	CcSEcCtD
Mepenzolate—Clemastine—CYP3A4—type 2 diabetes mellitus	0.00115	0.153	CrCbGaD
Mepenzolate—Vomiting—Losartan—type 2 diabetes mellitus	0.00113	0.00163	CcSEcCtD
Mepenzolate—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.00112	0.00162	CcSEcCtD
Mepenzolate—Nausea—Irbesartan—type 2 diabetes mellitus	0.00112	0.00162	CcSEcCtD
Mepenzolate—Headache—Losartan—type 2 diabetes mellitus	0.00112	0.0016	CcSEcCtD
Mepenzolate—Asthenia—Ramipril—type 2 diabetes mellitus	0.0011	0.00157	CcSEcCtD
Mepenzolate—Nausea—Losartan—type 2 diabetes mellitus	0.00106	0.00152	CcSEcCtD
Mepenzolate—Dizziness—Ramipril—type 2 diabetes mellitus	0.00101	0.00145	CcSEcCtD
Mepenzolate—Vomiting—Ramipril—type 2 diabetes mellitus	0.000971	0.0014	CcSEcCtD
Mepenzolate—Headache—Ramipril—type 2 diabetes mellitus	0.000956	0.00137	CcSEcCtD
Mepenzolate—Nausea—Ramipril—type 2 diabetes mellitus	0.000907	0.0013	CcSEcCtD
Mepenzolate—Darifenacin—CYP3A4—type 2 diabetes mellitus	0.000819	0.109	CrCbGaD
Mepenzolate—Levomethadyl Acetate—CYP3A4—type 2 diabetes mellitus	0.000615	0.0822	CrCbGaD
Mepenzolate—Methadone—CYP1A2—type 2 diabetes mellitus	0.000545	0.0728	CrCbGaD
Mepenzolate—Dextropropoxyphene—CYP3A4—type 2 diabetes mellitus	0.000532	0.071	CrCbGaD
Mepenzolate—Fentanyl—CYP3A4—type 2 diabetes mellitus	0.000526	0.0703	CrCbGaD
Mepenzolate—Loperamide—CYP3A4—type 2 diabetes mellitus	0.000507	0.0677	CrCbGaD
Mepenzolate—Methadone—CYP3A4—type 2 diabetes mellitus	0.000361	0.0482	CrCbGaD
Mepenzolate—CHRM3—Metabolism—CYP2E1—type 2 diabetes mellitus	9.31e-05	0.000314	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—INSR—type 2 diabetes mellitus	9.28e-05	0.000313	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AGT—type 2 diabetes mellitus	9.26e-05	0.000312	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TRPC6—type 2 diabetes mellitus	9.23e-05	0.000311	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AGT—type 2 diabetes mellitus	9.23e-05	0.000311	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	9.22e-05	0.000311	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TRPC6—type 2 diabetes mellitus	9.2e-05	0.00031	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—SLC2A1—type 2 diabetes mellitus	9.2e-05	0.00031	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CYP1A2—type 2 diabetes mellitus	9.2e-05	0.00031	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	9.19e-05	0.00031	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AGTR2—type 2 diabetes mellitus	9.18e-05	0.000309	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AGTR2—type 2 diabetes mellitus	9.15e-05	0.000308	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AGT—type 2 diabetes mellitus	9.14e-05	0.000308	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TRPC6—type 2 diabetes mellitus	9.12e-05	0.000307	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	9.1e-05	0.000307	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AGTR2—type 2 diabetes mellitus	9.06e-05	0.000305	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—CCR5—type 2 diabetes mellitus	9.06e-05	0.000305	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—CCR5—type 2 diabetes mellitus	9.03e-05	0.000304	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CYP3A4—type 2 diabetes mellitus	8.97e-05	0.000302	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—CCR5—type 2 diabetes mellitus	8.94e-05	0.000301	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—C3—type 2 diabetes mellitus	8.85e-05	0.000298	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—C3—type 2 diabetes mellitus	8.82e-05	0.000297	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—GCG—type 2 diabetes mellitus	8.82e-05	0.000297	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—SLC2A4—type 2 diabetes mellitus	8.82e-05	0.000297	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EDNRB—type 2 diabetes mellitus	8.79e-05	0.000296	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EDNRB—type 2 diabetes mellitus	8.76e-05	0.000295	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—C3—type 2 diabetes mellitus	8.74e-05	0.000294	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EDNRB—type 2 diabetes mellitus	8.68e-05	0.000292	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	8.56e-05	0.000288	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PSMD6—type 2 diabetes mellitus	8.54e-05	0.000288	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HTR2C—type 2 diabetes mellitus	8.54e-05	0.000288	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	8.53e-05	0.000287	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PSMD6—type 2 diabetes mellitus	8.51e-05	0.000287	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HTR2C—type 2 diabetes mellitus	8.51e-05	0.000287	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	8.45e-05	0.000285	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	8.43e-05	0.000284	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	8.43e-05	0.000284	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AGT—type 2 diabetes mellitus	8.41e-05	0.000283	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AGT—type 2 diabetes mellitus	8.38e-05	0.000282	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EDNRA—type 2 diabetes mellitus	8.3e-05	0.00028	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AGT—type 2 diabetes mellitus	8.3e-05	0.00028	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EDNRA—type 2 diabetes mellitus	8.28e-05	0.000279	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—CALM1—type 2 diabetes mellitus	8.27e-05	0.000279	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CYBA—type 2 diabetes mellitus	8.27e-05	0.000279	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—CALM1—type 2 diabetes mellitus	8.24e-05	0.000278	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CYBA—type 2 diabetes mellitus	8.24e-05	0.000278	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	8.2e-05	0.000276	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	8.16e-05	0.000275	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CYBA—type 2 diabetes mellitus	8.16e-05	0.000275	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	8.13e-05	0.000274	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	8.1e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PLAT—type 2 diabetes mellitus	8.09e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—GHRL—type 2 diabetes mellitus	8.09e-05	0.000273	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PLAT—type 2 diabetes mellitus	8.07e-05	0.000272	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—GHRL—type 2 diabetes mellitus	8.07e-05	0.000272	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	8.02e-05	0.00027	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.99e-05	0.000269	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PLAT—type 2 diabetes mellitus	7.99e-05	0.000269	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GHRL—type 2 diabetes mellitus	7.99e-05	0.000269	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.97e-05	0.000268	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CALCA—type 2 diabetes mellitus	7.89e-05	0.000266	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	7.77e-05	0.000262	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	7.75e-05	0.000261	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	7.67e-05	0.000258	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—GNB3—type 2 diabetes mellitus	7.6e-05	0.000256	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PPARGC1A—type 2 diabetes mellitus	7.6e-05	0.000256	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—HMOX1—type 2 diabetes mellitus	7.57e-05	0.000255	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	7.53e-05	0.000254	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	7.5e-05	0.000253	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	7.49e-05	0.000252	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	7.47e-05	0.000252	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CAT—type 2 diabetes mellitus	7.47e-05	0.000252	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	7.43e-05	0.00025	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—GCG—type 2 diabetes mellitus	7.4e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PTPN1—type 2 diabetes mellitus	7.4e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	7.4e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—GCG—type 2 diabetes mellitus	7.38e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PTPN1—type 2 diabetes mellitus	7.38e-05	0.000249	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	7.31e-05	0.000246	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GCG—type 2 diabetes mellitus	7.31e-05	0.000246	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	7.28e-05	0.000245	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	7.26e-05	0.000245	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	7.26e-05	0.000245	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—APOB—type 2 diabetes mellitus	7.25e-05	0.000244	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	7.23e-05	0.000244	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	7.19e-05	0.000242	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	7.16e-05	0.000241	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—GSTM1—type 2 diabetes mellitus	7.05e-05	0.000238	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.93e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—LPL—type 2 diabetes mellitus	6.92e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.9e-05	0.000233	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	6.84e-05	0.00023	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.8e-05	0.000229	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.8e-05	0.000229	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.78e-05	0.000229	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ADCY5—type 2 diabetes mellitus	6.78e-05	0.000228	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.78e-05	0.000228	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—GPX1—type 2 diabetes mellitus	6.75e-05	0.000228	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	6.72e-05	0.000226	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	6.71e-05	0.000226	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CD36—type 2 diabetes mellitus	6.58e-05	0.000222	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PPP2CA—type 2 diabetes mellitus	6.5e-05	0.000219	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.44e-05	0.000217	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.42e-05	0.000216	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.38e-05	0.000215	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.36e-05	0.000214	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	6.36e-05	0.000214	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—GNB3—type 2 diabetes mellitus	6.3e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AVP—type 2 diabetes mellitus	6.29e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.29e-05	0.000212	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AVP—type 2 diabetes mellitus	6.27e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.27e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.26e-05	0.000211	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.24e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.24e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—MTHFR—type 2 diabetes mellitus	6.23e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.22e-05	0.00021	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AVP—type 2 diabetes mellitus	6.21e-05	0.000209	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MMP3—type 2 diabetes mellitus	6.21e-05	0.000209	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF2—type 2 diabetes mellitus	6.18e-05	0.000208	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.17e-05	0.000208	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	6.16e-05	0.000207	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.15e-05	0.000207	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PPARA—type 2 diabetes mellitus	6.12e-05	0.000206	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	6.09e-05	0.000205	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—APOB—type 2 diabetes mellitus	6.08e-05	0.000205	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—APOB—type 2 diabetes mellitus	6.06e-05	0.000204	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.06e-05	0.000204	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1R—type 2 diabetes mellitus	6.04e-05	0.000203	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—APOB—type 2 diabetes mellitus	6e-05	0.000202	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.99e-05	0.000202	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.98e-05	0.000201	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.97e-05	0.000201	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—AGT—type 2 diabetes mellitus	5.92e-05	0.0002	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.91e-05	0.000199	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—CALM1—type 2 diabetes mellitus	5.82e-05	0.000196	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—LPL—type 2 diabetes mellitus	5.81e-05	0.000196	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—APOE—type 2 diabetes mellitus	5.8e-05	0.000196	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—LPL—type 2 diabetes mellitus	5.79e-05	0.000195	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—APOA1—type 2 diabetes mellitus	5.74e-05	0.000193	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—LPL—type 2 diabetes mellitus	5.73e-05	0.000193	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.69e-05	0.000192	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.67e-05	0.000191	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.61e-05	0.000189	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.45e-05	0.000184	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.43e-05	0.000183	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	5.38e-05	0.000181	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.35e-05	0.00018	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.33e-05	0.00018	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCR5—type 2 diabetes mellitus	5.28e-05	0.000178	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—C3—type 2 diabetes mellitus	5.23e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—C3—type 2 diabetes mellitus	5.21e-05	0.000176	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—C3—type 2 diabetes mellitus	5.16e-05	0.000174	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PPARG—type 2 diabetes mellitus	5.05e-05	0.00017	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.99e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.97e-05	0.000168	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.97e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AGT—type 2 diabetes mellitus	4.97e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.96e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—INS—type 2 diabetes mellitus	4.96e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AGT—type 2 diabetes mellitus	4.95e-05	0.000167	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.92e-05	0.000166	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.91e-05	0.000165	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AGT—type 2 diabetes mellitus	4.9e-05	0.000165	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.88e-05	0.000165	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.87e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—LEP—type 2 diabetes mellitus	4.87e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—APOE—type 2 diabetes mellitus	4.87e-05	0.000164	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—LEP—type 2 diabetes mellitus	4.85e-05	0.000163	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—APOE—type 2 diabetes mellitus	4.85e-05	0.000163	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.82e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.81e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—LEP—type 2 diabetes mellitus	4.81e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—APOE—type 2 diabetes mellitus	4.81e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.8e-05	0.000162	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.75e-05	0.00016	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.59e-05	0.000155	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.58e-05	0.000154	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—ALB—type 2 diabetes mellitus	4.54e-05	0.000153	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.53e-05	0.000153	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PIK3R1—type 2 diabetes mellitus	4.35e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—NOS3—type 2 diabetes mellitus	4.35e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.34e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.33e-05	0.000146	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IRS1—type 2 diabetes mellitus	4.29e-05	0.000144	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—INS—type 2 diabetes mellitus	4.16e-05	0.00014	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—INS—type 2 diabetes mellitus	4.15e-05	0.00014	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—INS—type 2 diabetes mellitus	4.1e-05	0.000138	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.09e-05	0.000138	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.08e-05	0.000137	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CCL2—type 2 diabetes mellitus	4.04e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.02e-05	0.000136	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.02e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IGF1—type 2 diabetes mellitus	4.01e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT2—type 2 diabetes mellitus	4.01e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—EGFR—type 2 diabetes mellitus	4e-05	0.000135	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.99e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—PTGS2—type 2 diabetes mellitus	3.98e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.97e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.97e-05	0.000134	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	3.95e-05	0.000133	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.82e-05	0.000129	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.81e-05	0.000128	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.77e-05	0.000127	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.65e-05	0.000123	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.65e-05	0.000123	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.64e-05	0.000122	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.64e-05	0.000122	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.6e-05	0.000121	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.6e-05	0.000121	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—RELA—type 2 diabetes mellitus	3.43e-05	0.000116	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—RELA—type 2 diabetes mellitus	3.42e-05	0.000115	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—RELA—type 2 diabetes mellitus	3.39e-05	0.000114	CbGpPWpGaD
Mepenzolate—CHRM1—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.12e-05	0.000105	CbGpPWpGaD
Mepenzolate—CHRM3—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.11e-05	0.000105	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.1e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.09e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	3.08e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.08e-05	0.000104	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.07e-05	0.000103	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—CASP3—type 2 diabetes mellitus	3.06e-05	0.000103	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—IL6—type 2 diabetes mellitus	3.04e-05	0.000102	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.93e-05	9.86e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.92e-05	9.83e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.89e-05	9.75e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.89e-05	9.73e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.89e-05	9.72e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.86e-05	9.63e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.84e-05	9.56e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.83e-05	9.53e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.8e-05	9.44e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—SRC—type 2 diabetes mellitus	2.7e-05	9.09e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—SRC—type 2 diabetes mellitus	2.69e-05	9.06e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—SRC—type 2 diabetes mellitus	2.66e-05	8.97e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.63e-05	8.85e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.62e-05	8.82e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.59e-05	8.74e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.41e-05	8.13e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.4e-05	8.1e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.38e-05	8.02e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.36e-05	7.97e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.36e-05	7.94e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.33e-05	7.86e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Metabolism—AKT1—type 2 diabetes mellitus	2e-05	6.73e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—IL6—type 2 diabetes mellitus	1.82e-05	6.12e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—IL6—type 2 diabetes mellitus	1.81e-05	6.1e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—IL6—type 2 diabetes mellitus	1.79e-05	6.04e-05	CbGpPWpGaD
Mepenzolate—CHRM1—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.68e-05	5.65e-05	CbGpPWpGaD
Mepenzolate—CHRM3—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.67e-05	5.63e-05	CbGpPWpGaD
Mepenzolate—CHRM2—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.65e-05	5.58e-05	CbGpPWpGaD
